Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
So the GLP-1s strike again: Eli Lilly’s Zepbound seems to work in obstructive sleep apnea as well. Beyond that, we see up close how Amylyx’s ALS drug — which it is pulling from the market — really didn’t differ much from placebo, and see more market and investment potential for psychedelics.
The need-to-know this morning
- Sage Therapeutics said an experimental drug failed to improve cognition versus a placebo in a mid-stage study of Parkinson’s disease. The company is conducting additional studies of the drug, called SAGE-718, in Huntington’s disease and Alzheimer’s disease, with results expected later this year.
- Brainstorm Cell Therapeutics, a developer of a cell therapy for ALS, said its co-CEO, Stacy Lindborg, is leaving the company.
- Future Pak, a privately held drug and nutraceutical manufacturer, made an unsolicited offer to acquire Vanda Pharmaceuticals.
Eli Lilly’s Zepbound shows efficacy in sleep apnea
Eli Lilly’s GLP-1 obesity drug, Zepbound, helped decrease the symptoms of obstructive sleep apnea in a Phase 3 study — allowing it to potentially become the first approved treatment for this disorder. The trial showed that obese or overweight patients with apnea who weren’t on PAP therapy had 25.3 fewer events per hour on an index measuring the amount of times breathing stops or is restricted while sleeping. In comparison, patients on placebo had 5.3 fewer events.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect